Opportunity
Conventional systems used for medical monitoring and therapeutic agent administration often operate as open-loop configurations, where physiological diagnostic monitoring is not electronically or directly linked in real time to the corresponding treatment. This division relies heavily on manual intervention by medical staff, which introduces inherent risks of treatment delays, operational inefficiencies, and management bottlenecks, particularly in fast-paced healthcare environments where multiple critical patients require simultaneous attention. Furthermore, traditional medical interventions predominantly focus on treating diseases only after acute or severe clinical symptoms have fully developed. Suppressing biological abnormalities after an onset is significantly more challenging than addressing conditions in their early, pre-symptomatic stages. Existing single-component medical devices generally lack the multifunctionality required to achieve both high-resolution temporospatial physiological recording and precise, localized drug delivery simultaneously.
Technology
This patent introduces an electroactive, stimuli-responsive hydrogel material and an organic multifunctional microneedle electronic array ($\mu$NTron) designed to establish closed-loop, feedback-driven medical intervention systems. The hydrogel material features an interpenetrating network (IPN) structure formed by one-step in-situ polymerization, utilizing $N$-(3-Sulfopropyl)-$N$-methacroyloxyethyl-$N,N$-dimethylammonium betaine (DMAPS) as a structural backbone electrostatically linked with poly(3,4-ethylenedioxythiophene) polystyrene sulfonate (PEDOT:PSS) as a conductive component, together with at least one crosslinking agent. The resulting hydrogel exhibits tissue-like mechanical elasticity, high conductivity, and excellent chronic biocompatibility. Fabricated into an array of addressable, flexible microneedles, the device performs continuous multi-channel electrophysiological signal recording (such as local field potentials) to continuously monitor pathological conditions. When early abnormal bioelectric signals (e.g., early seizure spikes) are detected, the system triggers real-time, dose-adaptive, and highly controlled drug delivery directly from individual preloaded hydrogel microneedle electrodes via low-voltage electro-osmosis, effectively interrupting pathological progression before full symptom outburst.
Advantages
- Closed-Loop Functionality: Combines real-time bioelectric signal detection and on-demand drug delivery within a single integrated platform.
- Tissue-Matching Modulus: Exhibits soft, brain-tissue-like mechanical elasticity, minimizing mechanical mismatch, contact resistance, and long-term tissue damage.
- High Conductive and Structural Stability: Features a stable interpenetrating polymer network ensuring low electrical impedance and long-term performance in biological environments.
- Low Invasiveness and Superior Biocompatibility: Microneedle design allows targeted, deep-tissue penetration while causing minimal inflammatory response or microglial activation over extended periods.
- Precise Dose-Adaptive Triggering: Enables controlled, voltage-driven drug release with spatial and temporal precision, preventing unwanted drug leakage while minimizing total dosage requirements.
Applications
- Neurotreatment and Anti-Seizure Intervention: Real-time detection and early preventative suppression of epileptic seizures.
- Deep Brain Stimulation (DBS) Probes: Miniaturized implantable probes for managing Parkinson’s disease and essential tremors.
- Neural Interfaces for Robotic Prostheses: Biocompatible bioelectrodes for advanced brain-machine interface systems.
- Cardiovascular and Spinal Cord Monitoring: Wearable or implantable diagnostic and therapeutic devices for heart failure or spinal cord injuries.
- Biocompatible Tissue Scaffolds: Electroactive materials for localized tissue repair in brain, cardiac, or skeletal muscle tissues.
